Neurontin en es it fr

Neurontin Brand names, Neurontin Analogs

Neurontin Brand Names Mixture

  • No information avaliable

Neurontin Chemical_Formula

C9H17NO2

Neurontin RX_link

http://www.rxlist.com/cgi/generic/gabapent.htm

Neurontin fda sheet

Neurontin FDA

Neurontin msds (material safety sheet)

Neurontin MSDS

Neurontin Synthesis Reference

G Satzinger et al., U.S. Pat. 4,024,175 (1977).

Neurontin Molecular Weight

171.237 g/mol

Neurontin Melting Point

162-166 oC

Neurontin H2O Solubility

4490 mg/L

Neurontin State

Solid

Neurontin LogP

0.828

Neurontin Dosage Forms

Capsule; Tablet (oral); Solution (oral)

Neurontin Indication

For the management of postherpetic neuralgia in adults and as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy.

Neurontin Pharmacology

Gabapentin, an analog of GABA, is used as an anticonvulsant to treat partial seizures, amyotrophic lateral sclerosis (ALS), and painful neuropathies. Potential uses include monotherapy of refractory partial seizure disorders, and treatment of spasticity in multiple sclerosis, tremor. mood disorders, and attenuation of disruptive behaviors in dementia. Gabapentin has high lipid solubility, is not metabolized by the liver, has no protein binding, and doesn't possess the usual drug interactions.

Neurontin Absorption

Rapid. Absorbed in part by the L-amino acid transport system, which is a carrier-mediated, saturable transport system; as the dose increases, bioavailability decreases. Bioavailability ranges from approximately 60% for a 900 mg dose per day to approximately 27% for a 4800 milligram dose per day. Food has a slight effect on the rate and extent of absorption of gabapentin (14% increase in AUC).

Neurontin side effects and Toxicity

Symptoms of overdose include ataxia, labored breathing, ptosis, sedation, hypoactivity, and excitation.

Neurontin Patient Information

Patients should be instructed to take Neurontin only as prescribed.

Patients should be advised that Neurontin may cause dizziness, somnolence and other symptoms and signs of CNS depression. Accordingly, they should be advised neither to drive a car nor to operate other complex machinery until they have gained sufficient experience on Neurontin to gauge whether or not it affects their mental and/or motor performance adversely. Patients who require concomitant treatment with morphine may experience increases in gabapentin concentrations. Patients should be carefully observed for signs of CNS depression, such as somnolence, and the dose of Neurontin or morphine should be reduced appropriately.

Neurontin Organisms Affected

Humans and other mammals